Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 1 14Phase 3 11Phase 1/2 3Phase NA 1Phase 2/3 1

Status

Recruiting 13Completed 12Unknown 5Terminated 5Active not recruiting 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Genitourinary 1

Conditions

Breast Neoplasms 2Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Diseases 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × palbociclib × Clear all
NCT05468697 2026-01-23

MK-6482-024

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
60 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
44 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT02605486 2025-07-03

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
46 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡